Treatment of Wilson's disease with zinc: III. Prevention of reaccumulation of hepatic copper.

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Journal of Laboratory and Clinical Medicine

• Publication date

  1987-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.5555/URI:PII:0022214387901351PMID 3572199
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 3 years of continuous oral zinc therapy in 4 patients with Wilson's disease

  1983cited by this paper
• Oral zinc therapy for Wilson's disease.

  1983cited by this paper
• Oral zinc therapy for Wilson's disease.

  1983cited by this paper
• Establishment of a new therapy for Wilson's disease: Negative copper balance of Wilson's disease patients on oral zinc therapy

  1982cited by this paper
• Whole body surface loss of trace metals in normal males.

  1981cited by this paper
• Regulation of intestinal metallothionein biosynthesis in rats by dietary zinc.

  1981cited by this paper
• Treatment of Wilson's disease with oral zinc

  1981cited by this paper
• Wilson's disease.

  1981cited by this paper
• Evidence of dietary copper and zinc deficiencies.

  1979cited by this paper
• Intestinal metallothionein and the mutual antagonism between copper and zinc in the rat.

  1979cited by this paper
• Oral zinc sulphate as long-term treatment in Wilson's disease (hepatolenticular degeneration).

  1979cited by this paper
• Mammalian zinc homeostasis: requirement for RNA and metallothionein synthesis.

  1975cited by this paper
• Prevention of Wilson's disease in asymptomatic patients.

  1968cited by this paper
• CURRENT THERAPEUTICS. 192. PENICILLAMINE.

  1963cited by this paper
• CURRENT THERAPEUTICS. 192. PENICILLAMINE.

  1963cited by this paper

• The Role of Zinc in the Treatment of Wilson’s Disease

  2022cites this paper
• Low copper levels measured in the aortic wall of New Zealand patients with non-syndromic ascending thoracic aortic aneurysm

  2022cites this paper
• Other Alimentary Tract and Metabolism Products ( A 16)

  2021cites this paper
• Clinical and immunological effects and biomarkers of zinc deficiency

  2020cites this paper
• Treatment of Wilson Disease with Zinc Salts

  2019cites this paper
• WTX101 – an investigational drug for the treatment of Wilson disease

  2018cites this paper
• Kanatzidis and Coucouvanis , “ Structure of Bis ( tetraethy lammonium ) tetrathiomolybdte ( VI ) , 2 CHN " MoS

  2017cites this paper
• The Modern Treatment of Wilson's Disease

  2015cites this paper
• Wilson’s disease: a review of treatment options with a focus on zinc therapy

  2012cites this paper
• Zinc toxicity: from "no, never" to "hardly ever".

  2011cites this paper
• Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease.

  2011cites this paper
• Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease

  2009cites this paper
• Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases.

  2009cites this paper
• Myelopolyneuropathy and pancytopenia due to copper deficiency and high zinc levels of unknown origin II. The denture cream is a primary source of excessive zinc.

  2009cites this paper
• Withdrawal of penicillamine from zinc sulphate-penicillamine maintenance therapy in Wilson's disease: promising, safe and cheap.

  2008cites this paper
• Evaluation of copper toxicity in isolated human peripheral blood mononuclear cells and it's attenuation by zinc: ex vivo

  2006cites this paper
• Neurodegenerative Diseases: Neurological aspects of Wilson's disease

  2005cites this paper
• Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy.

  2003cites this paper
• Wilson's Disease

  2003cites this paper
• Zinc acetate for the treatment of Wilson’s disease

  2001cites this paper
• Treatment of Wilson's disease with zinc XVI: treatment during the pediatric years.

  2001cites this paper
• Treatment of Wilson's disease with zinc. XVII: Treatment during pregnancy

  2000cites this paper
• Raulin award lecture: Wilson's disease therapy with zinc and tetrathiomolybdate

  2000cites this paper
• Inhibition of carboxypeptidase A by D-penicillamine: mechanism and implications for drug design.

  2000cites this paper
• Recognition, Diagnosis, and Management of Wilson's Disease (44460)

  2000cites this paper
• Penicillamine should not be used as initial therapy in Wilson's disease

  1999cites this paper
• Diagnosis and treatment of Wilson's disease.

  1999cites this paper
• Treatment of Wilson's disease with zinc.

  1999cites this paper
• Diagnosis and Treatment of Wilson's Disease

  1999cites this paper
• Treatment of Wilson's disease with zinc: XV long-term follow-up studies.

  1998cites this paper
• Zinc Acetate Treatment in Wilson's Disease

  1998cites this paper
• Trace Elements in Head and Neck Cancer Patients: Zinc Status and Immunologic Functions

  1997cites this paper
• Trace elements in head and neck cancer patients: zinc status and immunologic functions.

  1997cites this paper
• Ocular copper deposition associated with benign monoclonal gammopathy and hypercupremia.

  1996cites this paper
• Treatment of Wilson Disease With Ammonium Tetrathiomolybdate: III. Initial Therapy in a Total of 55 Neurologically Affected Patients and Follow-up With Zinc Therapy

  1996cites this paper
• UPDATE ON METABOLIC LIVER DISEASE

  1996cites this paper
• Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy.

  1996cites this paper
• Pediatric gastroenterology. Update on metabolic liver disease.

  1996cites this paper
• Zinc deficiency in women, infants and children.

  1996cites this paper
• Zinc: The Biology and Therapeutics of an Ion

  1996cites this paper
• Plasma Copper and Antioxidant Status in Wilson's Disease

  1995cites this paper
• Interactions of zinc and molybdenum with copper in therapy of Wilson's disease.

  1995cites this paper
• Practical Recommendations and New Therapies for Wilson’s Disease

  1995cites this paper
• Copper-associated hepatopathies in dogs.

  1995cites this paper
• Nutrition and environmental health. Proceedings of a symposium. Anaheim, California, April 25-26, 1994.

  1995cites this paper
• Elevated plasma ceruloplasmin in insulin-dependent diabetes mellitus: evidence for increased oxidative stress as a variable complication.

  1995cites this paper
• Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients.

  1994cites this paper
• Treatment of Wilson's disease with zinc. XIII: Therapy with zinc in presymptomatic patients from the time of diagnosis.

  1994cites this paper
• Zinc: health effects and research priorities for the 1990s.

  1994cites this paper
• Burn severity, copper dose, and plasma ceruloplasmin in burned children during total parenteral nutrition.

  1993cites this paper
• Biochemistry of Zinc

  1993cites this paper
• Wilson's disease with cerebral manifestation: monitoring therapy by CSF copper concentration

  1993cites this paper
• Treatment of Wilson's disease with zinc XII: dose regimen requirements.

  1993cites this paper
• Fatal deterioration of Wilson's disease after institution of oral zinc therapy.

  1993cites this paper
• Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents.

  1993cites this paper
• Interactions of Zinc with Other Micronutrients

  1993cites this paper
• Essentiality and toxicity of zinc.

  1993cites this paper
• O zinco no tratamento de degeneração hepatolenticular a propósito de três casos: three case reports

  1992cites this paper
• Use of zinc acetate to treat copper toxicosis in dogs.

  1992cites this paper
• Penicillamine hepatotoxicity in the treatment of Wilson's disease.

  1992cites this paper
• [Zinc in the treatment of hepatolenticular degeneration: report of 3 cases].

  1992cites this paper
• Role of metallothionein in human health.

  1992cites this paper
• Oral zinc as initial therapy in Wilson's disease: two years of continuous treatment in a 10‐year‐old child

  1992cites this paper
• Wilson Disease

  1992cites this paper
• Treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction.

  1992cites this paper
• Hepatic zinc in hemochromatosis.

  1991cites this paper
• Discovery of human zinc deficiency and studies in an experimental human model.

  1991cites this paper
• Diagnosis and characterization of presymptomatic patients with Wilson's disease and the use of molecular genetics to aid in the diagnosis.

  1991cites this paper
• Inhibition of copper absorption by zinc

  1991cites this paper
• Treatment of Wilson's disease with zinc. IX: Response of serum lipids.

  1991cites this paper
• Use of zinc-copper metabolic interactions in the treatment of Wilson's disease.

  1990cites this paper
• Human and Canine Inherited Copper Toxicosis: Copper Balance Regulation and Molecular Genetics of Its Impairment

  1990cites this paper
• Pancreaticobiliary secretion of zinc and copper in normal persons and patients with Wilson's disease.

  1990cites this paper
• Current Therapy of Chronic Liver Disease

  1990cites this paper
• Non-caeruloplasmin copper and ferroxidase activity in mammalian serum. Ferroxidase activity and phenanthroline-detectable copper in human serum in Wilson's disease.

  1989cites this paper
• Hepatic drug clearance in chronic liver disease: Can we expect to find a universal, quantitative marker of hepatic function?

  1989cites this paper
• Oral zinc sulphate as primary therapeutic intervention in a child with Wilson disease

  1989cites this paper
• Neurobiology of zinc and zinc-containing neurons.

  1989cites this paper
• Die Wilson-Erkrankung - Neue Alternativen zur D-Penicillamin-Behandlung?

  1989cites this paper
• Two and half years of oral zinc sulphate therapy in an adult patient with Wilson's disease.

  1989cites this paper
• Treatment of Wilson's disease with zinc. V. Changes in serum levels of lipase, amylase, and alkaline phosphatase in patients with Wilson's disease.

  1989cites this paper
• Treatment of Wilson's disease with zinc. VI. Initial treatment studies.

  1989cites this paper
• Deterioration of Wilson's Disease Following the Start of Penicillamine Therapy-Reply

  1989cites this paper
• Treatment of Wilson's disease with zinc. VII. Protection of the liver from copper toxicity by zinc-induced metallothionein in a rat model.

  1989cites this paper
• Presymptomatic Wilson's disease: Further questions and comments

  1989cites this paper
• Studies of cholecystokinin-stimulated biliary secretions reveal a high molecular weight copper-binding substance in normal subjects that is absent in patients with Wilson's disease.

  1988cites this paper
• Linkage of the Wilson disease gene to chromosome 13 in North-American pedigrees.

  1988cites this paper
• Copper toxicity in Wilson's disease: an absorbing problem.

  1988cites this paper
• Zinc-copper interaction provides a novel and apparently effective alternative therapy for Wilson's disease.

  1987cites this paper